In what Lawrence Livermore National Lab said is "a substantial milestone for supercomputing-aided drug design," LLNL and BridgeBio Oncology Therapeutics  today announced clinical trials have begun for ....

The post Livermore Lab and BridgeBio Announce Human Trials for HPC-Discovered Cancer Drug appeared first on High-Performance Computing News Analysis | insideHPC.

SEOUL, SOUTH KOREA and TEL AVIV, ISRAEL | April 04, 2024 — Quantum computing software company Classiq and Quantum Intelligence Corp. today announced the launch of joint research for drug development by applying quantum computing to pharmacology. The collaboration is under the auspices of Classiq’s Quantum Computing For Life Sciences & Healthcare Center, launched with NVIDIA […]

The post Classiq and Quantum Intelligence Partner on Drug Development appeared first on High-Performance Computing News Analysis | insideHPC.

The post Flatiron Institute Using Argonne HPC to Design Peptide-based Drugs with Quantum Mechanics appeared first on High-Performance Computing News Analysis | insideHPC.

PALO ALTO, Calif., April 18, 2023 — QC Ware, a provider of chemistry simulation and machine learning solutions, today announced the release of Promethium, a modern software-as-a-service (SaaS) quantum chemistry platform designed to accelerate pharmaceutical, chemical and materials discovery. Promethium’s platform offers a range of capabilities designed to help companies overcome various challenges in the […]

The post QC Ware Launches Promethium for Pharmaceutical,  Chemical and Materials Discovery appeared first on High-Performance Computing News Analysis | insideHPC.

[SPONSORED CONTENT]   In biomedical research it’s accelerate or perish. Drug discovery is a trial-and-error process driven by simulations – faster simulations, enabled by compute- and data-intensive technologies, mean more runs in less time, resulting in errors identified and solutions achieved. Established in 1946, the Oklahoma Medical Research Foundation is a nonprofit research institute with more than 450 staff and over 50 labs studying cancer, heart disease, autoimmune disorders and aging-related diseases. OMRF discoveries led to the first, U.S.-approved therapy targeting sickle cell disease and the first approved treatment for neuromyelitis optica spectrum disorder, an autoimmune disease.  The foundation’s research is enabled in part by advanced technology – accelerated clusters and high-performance data storage that support workloads fueled by massive data sets.

The post Silicon Mechanics Delivers 10x HPC Run Time Boost for Oklahoma Medical Research Foundation appeared first on High-Performance Computing News Analysis | insideHPC.

The post Dotmatics Launches Chemistry Solution for Small Molecule Drug Discovery appeared first on High-Performance Computing News Analysis | insideHPC.

The post Nvidia Partners with Schrödinger on Drug Discovery appeared first on High-Performance Computing News Analysis | insideHPC.

The post 3 National Labs Join ATOM Consortium for Drug Discovery appeared first on High-Performance Computing News Analysis | insideHPC.

Polarisqb has partnered with Fujitsu to create a ground-breaking drug discovery platform combining quantum-inspired technology, machine learning, hybrid quantum mechanics and molecular mechanics simulations (QM/MM). This new platform enables significantly faster, more cost-effective discovery of novel lead molecules to develop new drugs. Polarisqb and Fujitsu have begun a drug discovery project targeting Dengue Fever which has no approved treatments.

The post PolarisQB and Fujitsu Launch Drug Discovery Platform appeared first on High-Performance Computing News Analysis | insideHPC.

Schrödinger has entered into a three-year agreement with Google Cloud to substantially increase the speed and capacity of its physics-based computational platform for drug discovery. "We’re excited to harness Google Cloud’s highly scalable system to run extensive free energy calculations to assess binding affinities through our compute-intensive FEP+ application. This partnership also enables us to further leverage BigQuery to analyze important molecular properties nearly instantaneously," said Shane Brauner, Schrödinger’s Chief Information Officer. "This partnership is expected to allow us to expand the use of our physics-based computational platform to continue to rapidly explore very large swaths of chemical space."

The post Schrödinger Taps Google Cloud HPC Solution to Bolster Drug Discovery appeared first on High-Performance Computing News Analysis | insideHPC.